Regeneron Pharmaceuticals Inc. buy Canaccord Genuity Group Inc.
Summary
This prediction is currently active. With a performance of 6.88%, the BUY prediction by Canaccord_Genuity_Gr for Regeneron Pharmaceuticals Inc. is trending in the right direction. A total of €0.94 was paid as dividends for this prediction. This prediction currently runs until 19.05.27. The prediction end date can be changed by Canaccord_Genuity_Gr at any time. Canaccord_Genuity_Gr has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | -2.451% | -2.451% |
| iShares Core DAX® | 0.855% | 0.389% |
| iShares Nasdaq 100 | -0.989% | -4.400% |
| iShares Nikkei 225® | -1.781% | -11.216% |
| iShares S&P 500 | 0.057% | 0.778% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Stopped prediction by Canaccord_Genuity_Gr for Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc.
21.08.23
21.08.24
22.08.24

